Expectant mother at a doctor's appointment

Biotricity extends heart rate variability research to include fetal and maternal applications

Mobile wireless monitoring solution with high fidelity metrics could make non-invasive maternal/fetal monitoring a reality


REDWOOD CITY, Calif., Oct. 23, 2018 (GLOBE NEWSWIRE) — Biotricity Inc. (OTCQB:BTCY), a medical diagnostic and consumer healthcare technology company, today announced that it will be expanding the scope of a previously approved clinical investigation of fetal heart rate variability (fHRV) to include maternal HRV and other key physiologic metrics for maximum predictive accuracy and efficiency. This extension aligns well with the Company’s ongoing research into clinical HRV and continues to leverage its strategic relationships to conduct innovative collaborative research without losing intellectual property (IP) or incurring additional costs.

Biotricity’s concept solution aims to overcome the limitations inherent in current maternal/fetal monitoring solutions. Today, in the traditional pre-delivery non-stress test (NST) and during labor monitoring, fHRV is evaluated using decades-old techniques based on visual recognition. Low-quality ultrasound-based fHRV is substandard for a number of reasons because it is not precise enough for mathematical processing, is too sensitive to changes in fetal and maternal position, and it does not include any maternal heart rate variability (mHRV) information whatsoever. Conventional external monitoring of contractions is similarly imprecise because high quality, consistent monitoring requires that electrodes and sensors be inserted into the mother and/or attached to the baby which carries the risk of trauma, discomfort, and infection.

HRV is a measure of the variation in time between each heartbeat. A high HRV is a good indicator of greater cardiovascular fitness and resilience to stress, and thus a good indicator of overall health. It can also be used to differentiate between stable patients and those who may develop complications. Biotricity has observed and validated this capability in its initial clinical HRV study in the adult population, and it is well established in the delivery suite as well. A mobile, wireless and non-invasive maternal monitoring solution that incorporates HRV metrics will allow for real-time and real-life evaluation of both maternal and fetal health, which is especially important for higher-risk pregnancies.

The Company’s goal is to innovate and displace established maternal monitoring solutions with non-invasive monitoring and high-fidelity ECG, HRV, and respiration metrics combined with non-invasive quantitative contraction monitoring. High-risk pregnancies now account for 6 – 8 percent of all pregnancies in the U.S., due in part to a rise in existing maternal health conditions, such as high blood pressure and obesity, and older parental age at the time of pregnancy. High-risk pregnancies require extensive monitoring and care during the gestational period, and because high-risk pregnancies are on the rise, the maternal and fetal monitoring market is growing rapidly and is expected to be worth $2.3 Billion by 2019.

“We are targeting a previously untapped market and catering to previously un-met customer needs, because current maternal monitoring solutions do not offer an application that combines accuracy with comfort and the highest standards of non-invasive patient safety,” said Mr. Waqaas Al-Siddiq, Founder and CEO of Biotricity. “A first of its kind, our goal is to offer a new approach to gestational monitoring and then to take it one step further by integrating a range of key patient metrics for a holistic assessment of maternal and fetal health. If successful, this will be another utilization of Biotricity’s core technologies and clinical/consumer applications just like our FDA-approved Bioflux solution.”

To learn more, visit www.biotricity.com or follow on

Twitter: @biotricity_inc Facebook: www.facebook.com/biotricity/ or
LinkedIn: www.linkedin.com/company/biotricity-measuring-vitals

About Biotricity Inc.

Biotricity is a modern medical technology company focused on delivering innovative, remote biometric monitoring solutions to the medical and consumer markets, including diagnostic and post-diagnostic solutions for chronic conditions and lifestyle improvement. Biotricity’s R&D continues to focus on the preventative healthcare market, with a vision of putting health management into the hands of the individual. The company aims to support the self-management of critical and chronic conditions with the use of innovative solutions to ease the growing burden on the healthcare system. To learn more, visit www.biotricity.com.

Important Cautions Regarding Forward-Looking Statements

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements, which involve assumptions and describe our future plans, strategies, and expectations, are generally identifiable by use of the words “may,” “should,” “would,” “will,” “could,” “scheduled,” “expect,” “anticipate,” “estimate,” “believe,” “intend,” “seek,” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements may include, without limitation, statements regarding (i) the plans and objectives of management for future operations, including plans or objectives relating to the design, development and commercialization of Bioflux or any of the Company’s other proposed products or services, (ii) a projection of income (including income/loss), earnings (including earnings/loss) per share, capital expenditures, dividends, capital structure or other financial items, (iii) the Company’s future financial performance, (iv) the regulatory regime in which the Company operates or intends to operate and (v) the assumptions underlying or relating to any statement described in points (i), (ii), (iii) or (iv) above. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company’s current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences, many of which the Company has no control over. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the Company’s inability to obtain additional financing, the significant length of time and resources associated with the development of its products and related insufficient cash flows and resulting illiquidity, the Company’s inability to expand the Company’s business, significant government regulation of medical devices and the healthcare industry, lack of product diversification, existing or increased competition, results of arbitration and litigation, stock volatility and illiquidity, and the Company’s failure to implement the Company’s business plans or strategies. These and other factors are identified and described in more detail in the Company’s filings with the SEC. The Company assumes no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release.


Media contacts

McCoin & Smith Communications Inc.

Chris McCoin

Richard Smith

Investor relations:

Biotricity Investor Relations